Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors

Eur Urol. 2021 Jul;80(1):113. doi: 10.1016/j.eururo.2021.02.007. Epub 2021 Feb 13.

Author

J Alfred Witjes¹

Affiliation

¹ Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: [email protected].

PMID: 33593656
DOI: 10.1016/j.eururo.2021.02.007

No abstract available

Publication types

Comment

MeSH terms

B7-H1 Antigen
Carcinoma, Transitional Cell* / drug therapy
Humans
Immune Checkpoint Inhibitors
Platinum / therapeutic use
Prognosis
Urinary Bladder Neoplasms* / drug therapy
Urologic Neoplasms* / drug therapy

Substances

B7-H1 Antigen
Immune Checkpoint Inhibitors
Platinum